Novo Nordisk Rejects $75M in Hacker Demands as Pipeline Hopes and Patent Threats Collide
25.06.2026 - 22:21:38 | boerse-global.de
The Danish pharmaceutical giant is juggling a data breach of historic proportions, the looming expiration of key patents, and a high-stakes regulatory decision on its next-generation obesity therapy — all while its stock works its way back from a severe drawdown. Novo Nordisk’s shares, which had tumbled to a 12-month low of €30.25 in March, have rebounded roughly 39% and now trade near €42, recovering around 11–12% in just the past week. Yet the relative strength index sits at nearly 71, suggesting the rally has already pushed the stock into technically overbought territory.
The cyber incident stands out as one of the most serious in the pharmaceutical industry’s history. Two separate hacker groups, FulcrumSec and TheUSERS007, spent months burrowing into Novo Nordisk’s network. FulcrumSec exploited a GitHub access token discovered in March to clone internal repositories and extract further credentials, while TheUSERS007 independently infiltrated the same environment. Together they exfiltrated more than 1.3 terabytes of data encompassing over 700,000 files — including source code, clinical trial results, details on marketed and unapproved drugs, internal artificial intelligence models, and information on roughly 11,500 pseudonymised study participants.
FulcrumSec demanded $25 million in silence money; TheUSERS007 asked for $50 million. Novo Nordisk paid nothing. After the extortion attempt collapsed, FulcrumSec began offering the stolen data for sale on the dark web. The haul is especially sensitive because it covers pipeline assets such as Amycretin and CagriSema, as well as five entirely undisclosed drug programmes. The company has brought in external cybersecurity experts, temporarily shut down some internal IT systems, and informed the relevant authorities. Novo Nordisk insists that core business operations remain unaffected and that the clinical data contain no direct patient identifiers, but formal investigations by data-protection regulators in major markets could still lead to fines or binding orders.
Amid the crisis, Novo Nordisk has been steadily buying back its own shares. A programme launched in early February 2026 authorises repurchases of up to 15 billion Danish kroner over twelve months. Between programme inception and mid-June, the company had acquired roughly 21 million B-shares for about 5.6 billion kroner. In the week spanning 15 to 19 June alone, it picked up approximately 1.075 million B-shares. The buyback provides a floor for the stock as the company faces headwinds that are anything but temporary.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Patent cliffs are the most immediate commercial threat. Semaglutide patents expire in 2026 in Canada, India, and China, and generic versions are already being offered in India at discounts of up to 80%. Those markets, long seen as growth drivers, could see a sharp erosion in sales. At the same time, Eli Lilly continues to tighten the competitive grip on the GLP-1 space. Its oral GLP-1, Foundayo, reached the US market in April 2026, directly challenging Novo Nordisk’s oral Wegovy pill. On the conference circuit, Lilly unveiled strong data for Retatrutid, a triple-agonist combination that could leapfrog Novo’s pipeline, including CagriSema.
Pressure on pricing is also coming from Washington. The US Inflation Reduction Act’s Medicare price negotiation provisions apply to Ozempic as of 2026. Novo Nordisk has already conceded some price reductions in the US market and warned that the current year would be difficult. Production capacity remains a structural bottleneck: despite investing more than €6.5 billion in expanding manufacturing in 2025, the company cannot keep up with the explosive demand for GLP-1 therapies.
What keeps the bull case alive is the performance of the oral Wegovy pill. Approved by the US Food and Drug Administration in December 2025, the tablet launched nationally in January 2026 and had surpassed 3 million prescriptions by June. A UK approval followed that same month. The oral format opens up a patient segment that has largely shunned injections, and early uptake has been strong. Meanwhile, at the American Diabetes Association’s annual meeting in June 2026, Novo Nordisk presented phase 3 data for CagriSema, a fixed-dose combination that showed significant reductions in HbA1c and body weight. A US approval decision in obesity is expected before the end of 2026 — a clear catalyst that could drive the next leg of the stock’s recovery.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The bear case, however, is equally potent. Even if CagriSema gets the green light, generic competition in emerging markets could undercut margins faster than the company can compensate with new product revenue. Eli Lilly’s Retatrutid could also prove superior in both efficacy and market penetration, flipping Novo’s pipeline lead into a second-place chase. And the cyber attack raises the risk of regulatory penalties, lawsuits, or IP leakage that could erode Novo’s competitive moat.
Two milestones will dominate the second half of the calendar: the FDA’s verdict on CagriSema and the monthly prescription data for the Wegovy pill. The next concrete checkpoint comes even sooner — the second-quarter earnings report due on 5 August. That release will show whether Novo Nordisk can reaffirm its full-year guidance despite the data heist, the patent cliff, and the intensifying fight for GLP-1 dominance. The stock’s recent rebound suggests investors are giving the company the benefit of the doubt, but the next few months will reveal whether that optimism has fundamental support — or is merely a technical recovery waiting to fade.
Ad
Novo Nordisk Stock: New Analysis - 25 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
